Tempus AI Q3 revenue $180.9M (+33% YoY), net loss $75.8M, agrees to buy Ambry Genetics for $600M

Tempus AI, Inc.

Q3 revenue $180.9M (+33% YoY); net loss $75.8M (incl. $22.2M stock comp); Adj EBITDA -$21.8M (improved $14.4M YoY).
FY2024 guidance: revenue ~$700M (~32% growth), Adj EBITDA ~($105M), improvement of ~$50M over 2023.
Acquired Ambry Genetics for $600M ($375M cash + $225M shares); Ambry expects >$300M rev, >$40M EBITDA in CY2024.
Data & services rev +64.4% YoY, Insights rev +86.6%; Genomics unit growth 23.9%, rev +20.3%.
Debt financing: $300M increase from Ares; cash & marketable securities $466.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.